| Literature DB >> 35581568 |
Louise Østergaard Andersen1,2, Hanne Vebert Olesen1,2, Anne Helene Spannow1,2, Sune Leisgaard Mørck Rubak3,4.
Abstract
BACKGROUND: Nasal tracheal aspiration (NTA) is a frequently used diagnostic method to assess of infections in the lower airways. However, the validity of the method has not previously been compared to bronchoalveolar lavage (BAL) in non-intubated children with a lung disease. We hypothesised that NTA performed by health professionals using the nares vocal cord distance to be placed at the entrance of the trachea, will result in same finding of bacteria in the lower airways as the gold standard of BAL.Entities:
Keywords: Bronchoalveolar lavage; Cronic lung disease; Cystic fibrosis; Nasal tracheal aspiration; Paediatrics
Mesh:
Year: 2022 PMID: 35581568 PMCID: PMC9112497 DOI: 10.1186/s12890-022-01992-2
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Diagnosis, antibiotic treatment and bacteria—Sim, SN, SP, PPV, NPV compared to all samples
| NTA | p-value | |||||
|---|---|---|---|---|---|---|
| Positive | Negative | Results | 95% CI | |||
| Statistics by diagnosis | ||||||
| BAL | Positive | 73 | 26 | Sim: 122 (71%) | 63–79 | |
| Negative | 25 | 49 | SN: 74% | 64–81 | ||
| SP: 66% | 55–76 | |||||
| PPV: 75% | 65–82 | |||||
| NPV: 65% | 54–75 | |||||
| BAL | Positive | 35 | 26 | Sim: 84 (49%) | 41–56 | |
| Negative | 25 | 49 | SN: 35% | 27–45 | ||
| 38 samples had different growth composition | SP: 66% | 55–76 | ||||
| PPV: 36% | 27–46 | |||||
| NPV: 64% | 54–64 | |||||
| BAL | Positive | 24 | 2 | Sim: 29 (88%) | 73–95 | ( |
| Negative | 2 | 5 | SN: 92% | 76–99 | ( | |
| SP: 71% | 36–95 | (0.58) | ||||
| PPV: 92% | 76–99 | ( | ||||
| NPV: 71% | 36–95 | (0.51) | ||||
| BAL | Positive | 13 | 2 | Sim: 18 (55%) | 38–70 | (0.50) |
| Negative | 2 | 5 | SN: 50% | 32–68 | (0.10) | |
| 11 samples had different growth composition | SP: 71% | 36–95 | (0.58) | |||
| PPV: 50% | 32–68 | (0.13) | ||||
| NPV: 71% | 36–95 | (0.51) | ||||
| BAL | Positive | 12 | 6 | Sim: 26 (72%) | 56–84 | (0.84) |
| Negative | 4 | 14 | SN: 67% | 44–83 | (0.39) | |
| SP: 78% | 55–91 | (0.16) | ||||
| PPV: 75% | 51–90 | (0.90) | ||||
| NPV: 70% | 48–86 | (0.56) | ||||
| BAL | Positive | 4 | 6 | Sim: 18 (50%) | 35–66 | (0.88) |
| Negative | 4 | 14 | SN: 22% | 9–45 | (0.13) | |
| 8 samples had different growth composition | SP: 78% | 55–91 | (0.16) | |||
| PPV: 25% | 10–50 | (0.21) | ||||
| NPV: 70% | 48–86 | (0.56) | ||||
| Positive | 29 | 14 | Sim: 47 (63%) | 51–73 | (0.26) | |
| Negative | 14 | 18 | SN: 67% | 53–80 | (0.36) | |
| SP: 56% | 40–72 | (0.13) | ||||
| PPV: 67% | 53–80 | (0.26) | ||||
| NPV: 56% | 40–72 | (0.18) | ||||
| Positive | 11 | 14 | Sim: 29 (39%) | 29–50 | (0.16) | |
| Negative | 14 | 18 | SN: 26% | 15–40 | (0.16) | |
| 18 samples had different growth composition | SP: 56% | 40–72 | (0.13) | |||
| PPV: 26% | 15–40 | (0.12) | ||||
| NPV: 56% | 40–72 | (0.18) | ||||
| BAL | Positive | 8 | 4 | Sim: 20 ( 69%) | 51–83 | (0.89) |
| Negative | 5 | 12 | SN: 67% | 39–86 | (0.43) | |
| SP: 71% | 47–87 | (0.6) | ||||
| PPV: 62% | 36–82 | (0.18) | ||||
| NPV: 75% | 51–90 | (0.29) | ||||
| BAL | Positive | 7 | 4 | Sim: 19 (66%) | 47–80 | (0.083) |
| Negative | 5 | 12 | SN: 58% | 32–81 | ( | |
| 1 samples had different growth composition | SP: 71% | 47–87 | (0.6) | |||
| PPV: 54% | 29–77 | (0.06) | ||||
| NPV: 75% | 51–90 | (0.29) | ||||
| Statistics concerning antibiotic treatment | ||||||
| BAL | Positive | 23 | 5 | Sim: 42 ( 72%) | 60–82 | (0.81) |
| Negative | 11 | 19 | SN: 82% | 64–92 | (0.21) | |
| SP: 63% | 46–78 | (0.68) | ||||
| PPV: 68% | 51–81 | (0.38) | ||||
| NPV: 79% | 60–91 | ( | ||||
| BAL | Positive | 13 | 5 | Sim: 32 (55%) | 43–67 | (0.40) |
| Negative | 11 | 19 | SN: 46% | 30–64 | (0.13) | |
| 10 samples had different growth composition | SP: 63% | 46–78 | (0.68) | |||
| PPV: 38% | 24–55 | (0.78) | ||||
| NPV: 79% | 54–91 | ( | ||||
| BAL | Positive | 50 | 21 | Sim: 80 (70%) | 61–77 | (0.96) [0.79]d |
| Negative | 14 | 30 | SN: 70% | 59–80 | (0.48) [0.09] | |
| SP: 68% | 53–80 | (0.72) [0.51] | ||||
| PPV: 78% | 67–87 | (0.44) [0.15] | ||||
| NPV: 59% | 45–71 | (0.30) [ | ||||
| BAL | Positive | 22 | 21Uden | Sim: 52 (45%) | 36–54 | (0.55) [0.21] |
| Negative | 14 | 30 | SN: 31% | 21–43 | (0.48) [ | |
| 28 samples had different growth composition | SP: 68% | 32–53 | (0.72) [0.51] | |||
| PPV: 34% | 24–47 | (0.72) [0.60] | ||||
| NPV: 59% | 25–71 | (0.30) [ | ||||
| Statistics for all samples when common upper airway tract bacteria omitted | ||||||
| BAL | Positive | 35 | 26 | Sim: 98 (57%) | 49–64 | (0.12) |
| Negative | 11 | 63 | SN: 35% | 27–45 | (1.00) | |
| 38 samples had different growth composition | SP: 85% | 75–92 | ( | |||
| PPV: 42% | 32–52 | (0.25) | ||||
| NPV: 71% | 61–79 | (0.23) | ||||
| BAL | Positive | 40 | 26 | Sim: 93 (54%) | 46–61 | (0.32) |
| Negative | 21 | 53 | SN: 40% | 31–50 | (0.34) | |
| 33 samples had different growth composition | SP: 72% | 61–81 | (0.23) | |||
| PPV: 43% | 33–53 | (0.18) | ||||
| NPV: 67% | 56–76 | (0.69) | ||||
| BAL | Positive | 37 | 26 | Sim: 88 (51%) | 44–58 | (0.66) |
| Negative | 23 | 51 | SN: 37% | 29–47 | (0.70) | |
| 36 samples had different growth composition | SP: 69% | 58–78 | (0.55) | |||
| PPV: 39% | 29–49 | (0.56) | ||||
| NPV: 66% | 55–76 | (0.84) | ||||
| BAL | Positive | 40 | 25 | Sim: 107 (62%) | 54–69 | ( |
| Negative | 7 | 68 | SN: 41% | 32–51 | (0.25) | |
| 33 samples had different growth composition | SP: 91% | 82–95 | ( | |||
| PPV: 50% | 39–61 | ( | ||||
| NPV: 73% | 63–81 | (0.11) | ||||
Bold: p-values ≤ 0.05 are statistically significant
NTA nasal tracheal aspiration, BAL bronchoalveolar lavage, CI confidence interval, Sim similarity, SN sensitivity, SP specificity, PPV positive predictive value, NPV negative predictive value, H. influenza: Haemophilus influenza, Moraxella: Moraxella catarrhalis, S. pneumonia: Streptococcus pneumonia
aCoherence growth: Agreement is only based on positive growth or not in NTA and BAL
bConcordance bacteria: Complete concordance concerning pathogen bacteria between NTA and BAL
cThe (p-values) are calculated in relation to”All samples”
dThe [p-value] are calculated in relation to”with antibiotics”
eThe samples are placed in this group if the patient received antibiotics less than or three days before the examination or during the examinations—except if the treatment started the same day
fIf the bacteria was the only difference between the culture in NTA and BAL it was removed for the statistical analysis
gIf one of H. Influenza or Moraxella was the only difference between the culture in NTA and BAL it was removed for the statistical analysis
Demographic data of the samples
| Parameter | Number | |
|---|---|---|
| Number of samples | 173 | |
| Male/females ratio | 94/79 | |
| Age | ||
| 6 paired samples were performed in patients > 18 years and 6 young adults still treated at the paediatric department | 21 days–27 years |
*The 11 most common registered diagnosis
Complete similarity between NTA and BAL (all samples)
| NTA similar to BAL | NTA was not similar to BAL |
|---|---|
84 (35 true positive) (49 true negative) | 89 (26 with positive BAL and negative NTA) (25 with positive NTA and negative BAL) (38 with different positive culture) |
NTA nasal tracheal aspiration, BAL bronchoalveolar lavage
Statistics by diagnosis compared to other diagnoses
| Similarity | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|
| Coherence growtha | 0.504 | 0.060 | 0.928 | ||
| Concordance bacteriab | 0.678 | ||||
| Coherence growth | 0.141 | 0.142 | |||
| Concordance bacteria | 0.123 | ||||
| Coherence growth | 0.066 | 1 | 0.724 | ||
| Concordance bacteria | 0.377 | 0.528 | 0.753 | ||
| Coherence growth | 0.349 | 1 | 0.391 | 0.158 | |
| Concordance bacteria | 0.273 | 0.647 | 0.910 | ||
| Coherence growth | 0.792 | 1 | 0.518 | 0.260 | 0.655 |
| Concordance bacteria | 0.195 | ||||
| Coherence growth | 0.57 | 1 | 0.161 | 0.630 | 0.074 |
| Concordance bacteria | |||||
Bold: p-values ≤ 0.05 are statistically significant
PPV positive predictive value, NPV negative predictive value
aCoherence growth: Agreement is only based on positive growth or not in NTA and BAL
bConcordance bacteria: Complete concordance concerning pathogen bacteria between NTA and BAL
| Diagnosis code | Diagnosis | Diagnosis code | Diagnosis |
|---|---|---|---|
| DE849 | Cystic fibrosis | DJ450–DJ459 | Asthma |
| DJ981 | Atelectasis | ||
| DJ849 | Interstitial lung disease | DQ391 | Oesophageal atresia with trachea-esophageal fistula |
| DJ988A | Isolated ciliary dyskinesia | DP220 | Idiopathic infant respiratory distress syndrome |
| DJ982 | Interstitial lung emphysema | DP271 | Bronchopulmonal dysplasia arisen in the perinatal periode |
| DJ961 | Chronic respiratory insufficiency | DP271A | Moderate bronchopulmonal dysplasia arisen in the perinatal periode |
| DD849 | Immunodeficiency | DJ809 | Damage of the alveoli with respiratory failure (ARDS) |
| DJ479 | Bronchiectasis | DQ790 | Congenital diaphragmatic hernia |
| DJ841 | Other interstitial lung illness with fibrosis | DJ448B | Chronic asthmatic bronchitis |
| DJ429 | Chronic bronchitis | DJ980D | Tracheal stenosis |
| DJ84 | Other interstitial lung diseases | DJ840 | Alveoli or parieto-alveolar disease |
| DJ841C | Idiopathic lung fibrosis | DQ336 | Hyperplasia or dysplasia of the lung |
| DQ334 | Congenital bronchiectasis | DD143A | Benign tumour in bronchia |
| DJ848A | Allergic bronchopulmonal aspergillosis | DP288 | Other congenital airway disease |
| DD475 | Hypereosinophilic syndrome | DQ391A | Oesofageal atresia with congenital broncho? esophageal fistula |
| DJ984 | Other lung disease | ||
| DQ338 | Other congenital lung malformation | DQ322 | Bronchomalacia congenita |
| DQ339 | Congenital lung malformation | DQ349 | Congenital malformation in the respiratory system |
| DJ399 | Illness in the upper respiratory system | DQ321 | Other congenital malformation in trachea |
| DQ322 | Tracheal bronchomalaci | DJ39 | Other diseases in the upper respiratory system |
| DQ321B | Tracheal condromalaci | DQ324 | Other congenital bronchial malformation |
| DQ320 | Tracheomalacia congenita | DJ386 | Laryngo stenosis |
| DQ318H | Laryngeal condromalacia | DJ383V | Vocal cord dysfunction |